System and method for integration and display of data of insulin pumps and continuous glucose monitoring

Information

  • Patent Grant
  • 11607492
  • Patent Number
    11,607,492
  • Date Filed
    Wednesday, October 2, 2019
    4 years ago
  • Date Issued
    Tuesday, March 21, 2023
    a year ago
Abstract
A portable insulin pump can integrate and display data from a continuous glucose monitor (CGM) to allow a user to more readily determine whether any interaction with the pump is necessary. Data from the CGM can automatically be transmitted to the pump and can be displayed for user analysis or automatically analyzed to present recommendations to the user based on combined data from the CGM and the pump.
Description
FIELD OF THE INVENTION

The present invention relates to ambulatory infusions pumps and, more particularly, to integrating features of continuous glucose monitoring with insulin pumps.


BACKGROUND

There are many applications in academic, industrial, and medical fields that benefit from devices and methods that are capable of accurately and controllably delivering fluids, such as liquids and gases that have a beneficial effect when administered in known and controlled quantities. Such devices and methods can be particularly useful in the medical field where treatments for many patients include the administration of a known amount of a substance at predetermined intervals.


Insulin-injecting pumps have been developed for the administration of insulin for those suffering from both type I and type II diabetes. Recently, continuous subcutaneous insulin injection and/or infusion therapy with portable infusion devices has been adapted for the treatment of diabetes. Such therapy may include the regular and/or continuous injection or of insulin into the skin of a person suffering from diabetes and offer an alternative to multiple daily injections of insulin by an insulin syringe or an insulin pen. Such pumps can be ambulatory/portable infusion pumps that are worn by the user and may use replaceable cartridges. Examples of such pumps and various features that can be associated with such pumps include those disclosed in U.S. patent application Ser. No. 13/557,163, U.S. patent application Ser. No. 12/714,299, U.S. patent application Ser. No. 12/538,018, U.S. Provisional Patent Application No. 61/655,883, U.S. Provisional Patent Application No. 61/656,967 and U.S. Pat. No. 8,287,495, each of which is incorporated herein by reference.


Portable insulin pumps can be used in conjunction with continuous glucose monitoring (CGM) devices. A CGM provides a substantially continuous estimated blood glucose level through a transcutaneous sensor that measures analytes, such as glucose, in the patient's interstitial fluid rather than their blood. CGM systems typically consist of a transcutaneously-placed sensor, a transmitter and a monitor. A CGM system allows a patient or caregiver to insert a single sensor probe under the skin for multiple days. Thus, the patient is only required to perform a single moderately invasive action with a single entry point in the subdermal layer on, e.g., a weekly basis.


Ambulatory insulin infusion pumps typically allow the patient or caregiver to adjust the amount of insulin delivered, by a basal rate or a bolus, based on blood glucose data obtained by a blood glucose meter or CGM. Some ambulatory insulin infusion pumps may include the capability to interface with a blood glucose meter (BGM) or CGM such as, e.g., by receiving measured or estimated blood glucose levels and prompting the user to adjust the level of insulin being administered or planned for administration or, in cases of abnormally high blood glucose readings, prompting temporary cessation of insulin administration. These portable pumps may incorporate a BGM or CGM within the hardware of the pump or may communicate with a dedicated BGM or CGM via, wired or wireless data communication protocols. Such pumps may be particularly important in facilitating patient compliance and improved or more accurate treatment of diabetes. The delivery of insulin from a portable insulin pump making use of CGM data necessitates accurate and reliable CGM data output.


Generally, when CGM devices are used in conjunction with insulin pumps, the CGM device has a separate display from the insulin pump and the user must manually transfer data from the CGM to the pump in order for the pump to incorporate the data into its functioning. Even in instances where the pump can automatically receive CGM data, such as through a wireless connection, or incorporates the CGM in the pump, a user often must scroll through a number of screens of the pump to review the pump and CGM data and make a determination as to whether and how the data indicates that the user should activate the pump.


Therefore, there is a need for a system and a method for better integrating usage of CGM devices and data with insulin pumps.


SUMMARY OF THE INVENTION

A portable insulin pump can integrate and display data from a continuous glucose monitor (CGM) to allow a user to more readily determine whether any interaction with the pump is necessary. A screen of the pump, which can be a startup screen automatically displayed whenever the pump is turned on or activated from a sleep mode, can display a current glucose level of the user and historical glucose data obtained from the CGM as well as an estimate of the amount of un-metabolized insulin remaining in the user's body. This information allows the user to immediately assess whether any action needs to be taken with the pump, such as to deliver a bolus, without having to scroll through multiple pages and options to obtain the necessary information.


In an embodiment, a portable insulin pump includes a graphical user interface, a receiver adapted to receive information from a continuous glucose monitor and a processor functionally linked to the receiver and the graphical user interface. The processor can be configured to display a startup screen on the graphical user interface when the graphical user interface is activated from an inactive condition, such as being turned off or in sleep mode. The startup screen can display a current glucose level of a user and historical glucose level data based off of information received from the CGM at the receiver. The startup screen can also display an estimate of the amount of un-metabolized insulin remaining in the user's body.


In another embodiment, a portable insulin pump can integrate with a continuous glucose monitor to automatically calculate a recommended bolus for a user. When the user uses a blood sample to calibrate the CGM with an actual blood glucose reading, the CGM can automatically transmit that blood glucose value to the pump. The pump can then determine whether that value is above a threshold and, if so, automatically calculate a bolus of insulin to bring the user's blood glucose level below the threshold.


Certain embodiments are described further in the following description, examples, claims, and drawings. These embodiments will become more apparent from the following detailed description when taken in conjunction with the accompanying exemplary drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of an infusion pump according to an embodiment of the present invention.



FIG. 2 is a block diagram representing an embodiment of an infusion pump.



FIG. 3 depicts a screen shot of a home screen page of a graphical user interface of an infusion pump according to an embodiment of the present invention.



FIG. 4 is a partial schematic view depicting a continuous glucose monitor according to an embodiment of the present invention deployed on a patient.



FIG. 5 depicts a screen shot of a screen page of a graphical user interface of an infusion pump according to an embodiment of the present invention.



FIG. 6 depicts a screen shot of an unlock screen of a graphical user interface of an infusion pump according to an embodiment of the present invention.



FIG. 7 depicts a screen shot of a bolus recommendation screen of a graphical user interface of an infusion pump according to an embodiment of the present invention.



FIG. 8 is a flowchart of a method of recommending a correction bolus according to an embodiment of the present invention.





DETAILED DESCRIPTION

Provided herein are systems, devices and methods for integrating usage of ambulatory infusion pumps with continuous glucose monitoring devices. Some embodiments may include advances in the internal components, the control circuitry, and improvements in a user interface of the systems and devices. The advances may allow for a safer and more accurate delivery of medicament to a patient than is currently attainable today from other devices, systems, and methods. Although embodiments described herein may be discussed in the context of the controlled delivery of insulin, delivery of other medicaments, including, for example, glucagon, pramlintide, etc., as well as other applications are also contemplated. Device and method embodiments discussed herein may be used for pain medication, chemotherapy, iron chelation, immunoglobulin treatment, dextrose or saline IV delivery, or any other suitable indication or application. Non-medical applications are also contemplated.



FIG. 1 depicts an embodiment of a pump 12 such as an infusion pump that can include an internal pumping or delivery mechanism and reservoir for delivering medicament such as insulin to a patient and an output/display 44. The type of output/display 44 may vary as may be useful for a particular application. The type of visual output/display may include LCD displays, LED displays, plasma displays, OLED displays and the like. The output/display 44 may also be an interactive or touch sensitive screen 46 having an input device such as, for example, a touch screen comprising a capacitive screen or a resistive screen. The pump 12 may additionally include a keyboard or other input device known in the art for data entry, which may be separate from the display. The output/display 44 of the pump 12 may also include a capability to operatively couple to a secondary display device such as a laptop computer, mobile communication device such as a smartphone or personal digital assistant (PDA) or the like. Further details regarding such pump devices can be found in U.S. Patent Application No. 2011/0144586, which is incorporated herein by reference.


Some embodiments of an infusion system may include a portable infusion device, as described above and a remote commander device. In such an instance, the portable infusion device may include a suitably configured receiver and/or transmitter for communication with an external device such as a remote commander, as well as programming for directing the use of the device; and the remote commander may additionally include a suitably configured receiver and/or transmitter for communication with an external device such as a portable infusion device, as well as programming for directing the use of the device. For instance, the remote commander may include one or more of the functionalities described herein with respect to the portable infusion device. In addition, some GUI embodiments may be available to a user by downloading a software application onto the user's cell phone and/or PDA, which would allow the user to use their cell phone or PDA as a remote commander to the portable infusion device.



FIG. 2 illustrates a block diagram of some of the features that may be incorporated within the housing 26 of the pump 12. The pump 12 includes a processor 42 that functions to control the overall functions of the device. The infusion pump 12 may also include a memory device 30, a transmitter/receiver 32, an alarm 34, a speaker 36, a clock/timer 38, an input device 40, the processor 42, a user interface suitable for accepting input and commands from a user such as a caregiver or patient, a drive mechanism 48, and an estimator device 52. One embodiment of a user interface as shown in FIG. 2 is a graphical user interface (GUI) 60 having a touch sensitive screen 46 with input capability. The memory device 30 may be coupled to the processor 42 to receive and store input data and to communicate that data to the processor 42. The input data may include user input data and non-user/sensor input data. The input data from the memory device 30 may be used to generate therapeutic parameters for the infusion pump 12. The GUI 60 may be configured for displaying a request for the user to input data and for receiving user input data in response to the request, and communicating that data to the memory.


The processor 42 may communicate with and/or otherwise control the drive mechanism, output/display, memory, a transmitter/receiver and other components. In some embodiments, the processor 42 may communicate with a processor of another device, for example, a continuous glucose monitor (CGM), through the transmitter/receiver. The processor 42 may include programming that can be run to control the infusion of insulin or other medicament from the cartridge, the data to be displayed by the display, the data to be transmitted via the transmitter, etc. The processor 42 may also include programming that may allow the processor to receive signals and/or other data from an input device, such as a sensor that may sense pressure, temperature or other parameters. The processor 42 may determine the capacity of the drug delivery reservoir and/or the volume of fluid disposed in the drug delivery reservoir and may set therapeutic parameters based on its determination.


The processor 42 may also include additional programming to allow the processor 42 to learn user preferences and/or user characteristics and/or user history data. This information can be utilized to implement changes in use, suggestions based on detected trends, such as weight gain or loss. The processor can also include programming that allows the device to generate reports, such as reports based upon user history, compliance, trending, and/or other such data. Additionally, infusion pump device embodiments of the disclosure may include a “power off” or “suspend” function for suspending one or more functions of the device, such as suspending a delivery protocol, and/or for powering off the device or the delivery mechanism thereof. For some embodiments, two or more processors may be used for controller functions of the infusion pumps, including a high power controller and a low power controller used to maintain programming and pumping functions in low power mode, in order to save battery life.


The memory device 30 may be any type of memory capable of storing data and communicating that data to one or more other components of the device, such as the processor. The memory may be one or more of a Flash memory, SRAM, ROM, DRAM, RAM, EPROM and dynamic storage, for example. For instance, the memory may be coupled to the processor and configured to receive and store input data and/or store one or more template or generated delivery patterns. For example, the memory can be configured to store one or more personalized (e.g., user defined) delivery profiles, such as a profile based on a user's selection and/or grouping of various input factors, past generated delivery profiles, recommended delivery profiles, one or more traditional delivery profiles, e.g., square wave, dual square wave, basal and bolus rate profiles, and/or the like. The memory can also store, for example, user information, history of use, glucose measurements, compliance and an accessible calendar of events.


The housing 26 of the pump 12 may be functionally associated with an interchangeable and a removable glucose meter 20 and/or infusion cartridge 16. The infusion cartridge 16 may have an outlet port 54 that may be connected to an infusion set (not shown) via an infusion set connector 18. Further details regarding some embodiments of various infusion pumps can be found in U.S. Patent Application Publication No. 2011/0144586, which is hereby incorporated by reference.


Referring to FIG. 3, a front view of the pump 12 is depicted. The pump 12 may include a user interface, such as, for example, a user-friendly GUI 60 on a front surface 58 or other convenient location of the pump 12. The GUI 60 may include a touch-sensitive screen 46 that may be configured for displaying data, facilitating data entry by a patient, providing visual tutorials, as well as other interface features that may be useful to the patient operating the pump 12. A bolus object 82 can also be displayed on the screen 46.


Pump 12 can interface with a continuous glucose monitor (CGM) that provides a substantially continuous estimated glucose level through a transcutaneous sensor that measures analytes, such as glucose, in the patient's interstitial fluid rather than their blood. Referring to FIG. 4, a CGM system 100 according to an embodiment of the present invention is shown. The illustrated CGM system 100 includes a sensor 102 affixed to a patient 104 and is associated with the insulin infusion device 12. The sensor 102 includes a sensor probe 106 configured to be inserted to a point below the dermal layer (skin) of the patient 104. The sensor probe 106 is therefore exposed to the patient's interstitial fluid or plasma beneath the skin and reacts with that interstitial fluid to produce a signal that can be calibrated with the patient's blood glucose (BG) level. The sensor 102 includes a sensor body 108 that transmits data associated with the interstitial fluid to which the sensor probe is exposed. The data may be transmitted from the sensor 102 to the glucose monitoring system 100 via a wireless transmitter, such as a near field communication (NFC) radio frequency (RF) transmitter or a transmitter operating according to a “WiFi” or “Bluetooth” protocol or the like, or the data may be transmitted via a wire connector from the sensor 102 to the monitor system 100. Transmission of sensor data to the glucose monitor system 100 by wireless or wired connection is represented in FIG. 4 by the arrow line 112. Further detail regarding such systems and definitions of related terms can be found in, e.g., U.S. Pat. Nos. 8,311,749, 7,711,402 and 7,497,827, each of which is hereby incorporated by reference in its entirety.


In one embodiment, part of the CGM system 100 is incorporated into the pump 12 such that the processor 42 is adapted to receive the data from the sensor 102 and process and display the data on the display 44. In another embodiment, the CGM 100 is a separate device that communicates with the pump 12 through a wired or wireless link to transmit the CGM data to the pump 12.


Referring to FIG. 5, there can be seen a pump screen 110 incorporating pump 12 data and CGM data according to an embodiment of the present invention. Pump screen 110 can be displayed on the touch screen 46 of the GUI 60 on the front surface 58 of the pump 12. Screen 110 can include a battery life indicator 112 and an insulin indicator 114. Each indicator 112, 114 can include one or more of a graphical indication, shown in FIG. 4 as a plurality of indicator bars 116 and a textual indicator 118 such as a percentage or amount remaining. The time 120 and date 122 can also be displayed on screen 110. The screen 110 can also include an indication of the amount of insulin on board 124, that is, the amount of un-metabolized insulin already present in the user's body, as well as a time remaining object 126 counting down the amount of time the insulin on board is calculated to remain in the user's body. An options key 128 can allow a user to scroll through various pump operation options and a bolus object 130 can allow a user to begin programming a bolus of insulin.


With further reference to FIG. 5, information regarding the user's glucose level received from the CGM device can be incorporated and displayed on the pump screen 110 alongside insulin pump 12 data. The information can include the user's current glucose level 132 as well as a graphical representation 134 of historical glucose data that can be used, for example, to view glucose level trends and rates of change. A timeframe object 136 can be used to select a timeframe over which to view the historical data. The right side of the graph 134 can include a plurality of glucose values 138 forming the vertical axis of the graph 134. The horizontal axis of the graph 134 tracks the time period over which the data is displayed and can include hash marks 140 or other indicators, including numerical indicators, indicating equal divisions of the selected timeframe. The user's glucose level is therefore shown on the graph 134 as a function of time and can be shown as discrete points 142 as shown in FIG. 5. Alternatively, the glucose level versus time can be shown as a continuous line or curve. The graph 134 can also include a high glucose level indicator line 144 and a low glucose level indicator line 146 identifying predetermined patient specific thresholds that make it easy for a user to see when the user's glucose level has crossed a threshold. Although shown and described as being displayed in a graphical format, CGM data can also be displayed in a textual and numerical format on GUI 60 as well as audibly through, e.g., a speaker.


The pump screen 110 includes all data that the user needs to determine whether interaction with the pump is necessary. For example, for the user to determine whether or not to administer a bolus of insulin, the key information of the user's current glucose level 132, the amount of insulin on board 124 and historical glucose level data 144 indicating recent trends and rates of change is all displayed to the user on one convenient screen. In addition, whether underlying requirements for the pump to deliver a bolus are met, such as the battery life 112 of the pump and the amount of insulin 114 in the pump reservoir, can also be determined from the display of this information on the same screen 110.


The pump screen 110 shown in FIG. 5 can be a default or startup screen of the GUI 60. As a startup screen, pump screen 110 can be the first screen displayed on the GUI anytime the user powers the pump 12 on or activates the pump 12 from a sleep mode. This allows the user to immediately assess whether any action needs to be taken with the pump, such as to deliver a bolus, charge a battery or change a cartridge containing the insulin reservoir. The user can therefore take any necessary action with little more than a glance at the device, rather than having to scroll through multiple pages and options to determine whether action needs to be taken. In some embodiments, the pump 12 can also revert to the startup pump screen 110 whenever the GUI 60 has been inactive for a predetermined period of time and/or whenever a home key or home key sequence is entered.


If the user determines from the startup pump screen 110 that a bolus should be delivered, a deliver bolus command can also be begun directly from the screen 110 by selecting the deliver bolus object 130. If some other pump interaction is required, the user can access the necessary command with the options key 128. In some embodiments, before the user can deliver a bolus or otherwise change a pump parameter, the user must unlock the startup pump screen 110, such as by entering a specific numeric sequence or swiping along the touchscreen 46 in a specific manner. An unlock screen such as the unlock screen 111 shown in FIG. 6 can pop up over or in place of the startup pump screen 110 to provide for unlocking of the device. As shown in FIG. 6, in one embodiment unlock screen 111 includes a plurality of numerical indicators 148 with which the user enters a previously saved code to unlock the pump 12. Such an unlock procedure will prevent the user from accidentally altering pump operation when it is not intended. Aspects of these features are further explained in U.S. Provisional Patent Application Ser. No. 61/656,997 and in U.S. patent application Ser. No. 13/801,230 entitled “Preventing Inadvertent Changes in Ambulatory Medical Devices,” filed Mar. 13, 2013 by M. Rosinko, et al., each of which is hereby incorporated by reference.


Because CGM devices estimate blood glucose levels from analyzing interstitial plasma or fluid rather than blood as with blood glucose monitors that utilize a sample of blood obtained from, e.g., a finger stick, CGM devices generally are not as well-suited for accurate blood glucose monitoring. Accordingly, CGMs are most often used for identifying trends in blood glucose levels over time and for providing estimates thereof. However, to ensure that a CGM device is estimating the user's glucose level as accurately as possible, such devices require a user to calibrate with an actual blood sample several times a day that is then used to compare the user's actual blood glucose level with the glucose levels measured by the CGM. Typically, after this is done the user must then manually enter the blood glucose data into the pump to allow therapy parameters to be calculated based on the data. Aspects of advanced calibration techniques that may be used in such systems are found in U.S. patent application Ser. No. 13/841,028 entitled “Predictive Calibration” to Saint, the entirety of which is incorporated by reference.


However, in an embodiment of a pump 12 that communicates with a CGM and that integrates CGM data and pump data as described herein, the CGM can automatically transmit the blood glucose data determined from the calibration sample to the pump. The pump can then automatically determine therapy parameters based on the data. For example, if the calibration sample indicates that the user's blood glucose is over a high blood glucose threshold, the pump can automatically calculate an insulin bolus to bring the user's blood glucose below the threshold. In one embodiment, the pump presents the bolus to the user as a recommended bolus 150 on the GUI 60 that the user must approve in order for it to be delivered as shown in FIG. 7.


In some embodiments, a visual, audible or tactile alarm, or some combination of these, can automatically be issued to alert the user to a suggested action and reason for the action, such as a high blood glucose reading and corresponding recommended bolus.


Referring now to FIG. 8, a flowchart of a method of recommending a correction bolus 152 is depicted. At step 154, a user submitted blood sample is received at the CGM for calibration purposes. The blood glucose level of the blood sample is determined and then automatically transmitted to the pump at step 156. The pump determines at step 158 whether the blood glucose level is above a patient specific threshold level. If it is not, at step 160 no action is taken by the pump. If the level is above the threshold, then at step 162 the pump automatically calculates a correction bolus and displays the correction bolus as a recommendation to the user at step 164. If the user confirms the recommended bolus, the bolus is delivered to the user by the pump at step 166.


With regard to the above detailed description, like reference numerals used therein may refer to like elements that may have the same or similar dimensions, materials, and configurations. While particular forms of embodiments have been illustrated and described, it will be apparent that various modifications can be made without departing from the spirit and scope of the embodiments herein. Accordingly, it is not intended that the invention be limited by the forgoing detailed description.


The entirety of each patent, patent application, publication, and document referenced herein is hereby incorporated by reference. Citation of the above patents, patent applications, publications and documents is not an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these documents.


Modifications may be made to the foregoing embodiments without departing from the basic aspects of the technology. Although the technology may have been described in substantial detail with reference to one or more specific embodiments, changes may be made to the embodiments specifically disclosed in this application, yet these modifications and improvements are within the scope and spirit of the technology. The technology illustratively described herein may suitably be practiced in the absence of any element(s) not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation and use of such terms and expressions do not exclude any equivalents of the features shown and described or portions thereof and various modifications are possible within the scope of the technology claimed. Although the present technology has been specifically disclosed by representative embodiments and optional features, modification and variation of the concepts herein disclosed may be made, and such modifications and variations may be considered within the scope of this technology.

Claims
  • 1. A method of displaying information to aid in providing diabetes therapy with a portable insulin pump, comprising: receiving information pertaining to a glucose level of a user from a continuous glucose monitor;activating a graphical user interface of a portable insulin pump system from an inactive condition;displaying a startup screen on the graphical user interface automatically upon said activating the graphical user interface, including: displaying on the startup screen a current glucose level of the user based upon the information received from the continuous glucose monitor;displaying on the startup screen historical data relating to the glucose level of the user based upon information received from the continuous glucose monitor; anddisplaying on the startup screen an estimate of the amount of un-metabolized insulin in the user's body; anddisplaying on the startup screen a bolus delivery object selectable to initiate a programming of a bolus delivery of insulin,wherein displaying the startup screen on the graphical user interface automatically upon activating the graphical user interface includes displaying the startup screen in a locked configuration with at least one of the current glucose level, the historical data and the estimate of the amount of un-metabolized insulin in the user's body visible but not touch-selectable on the startup screen in the locked configuration to enable the user to assess whether any action needs to be taken with the portable insulin pump while the startup screen is in the locked configuration, andwherein the bolus delivery object on the startup screen is selectable to initiate programming of a bolus delivery of insulin when the startup screen is unlocked from the locked configuration.
  • 2. The method of claim 1, further comprising displaying one or more unlock indicators on the startup screen and further comprising receiving user input via the unlock indicators to unlock the startup screen from the locked configuration.
  • 3. The method of claim 2, wherein displaying one or more unlock indicators on the startup screen includes displaying the unlock indicators over the startup screen such that at least a portion of the startup screen is visible.
  • 4. The method of claim 1, wherein displaying on the startup screen historical data includes displaying the historical data in a graphical format depicting glucose levels of the user over time.
  • 5. The method of claim 4, wherein displaying the startup screen further includes displaying a timeframe object that is selectable to modify a timeframe over which the historical data is displayed, such that the historical data is displayed over the modified timeframe upon a subsequent activation of the startup screen.
  • 6. The method of claim 1, wherein displaying the startup screen further includes displaying at least one of a battery life indicator indicating a remaining life of a battery of the portable insulin pump and a reservoir level indicator indicating a remaining amount of insulin in an insulin reservoir of the portable insulin pump.
  • 7. The method of 1, wherein activating the graphical user interface of a portable insulin pump from an inactive condition includes activating the graphical user interface from a sleep mode.
  • 8. The method of claim 1, further comprising displaying the startup screen when no user input is received through the graphical user interface for a predetermined period of time.
  • 9. The method of claim 1, wherein activating the graphical user interface of a portable insulin pump system and displaying the startup screen on the graphical user interface activates the graphical user interface and displays the startup screen on a display of the portable insulin pump.
  • 10. The method of claim 1, wherein activating the graphical user interface of a portable insulin pump system and displaying the startup screen on the graphical user interface activates the graphical user interface and displays the startup screen on a display of a remote commander configured to control the portable insulin pump.
  • 11. A portable insulin pump system, comprising: a graphical user interface;a receiver adapted to receive information from a continuous glucose monitor; anda processor functionally linked to the receiver to obtain the information from the continuous glucose monitor and to the graphical user interface to control display of information on the graphical user interface, wherein the processor is configured to automatically display a startup screen on the graphical user interface when the graphical user interface is activated from an inactive condition, the startup screen including: a current glucose level of a user based off of the information received from the continuous glucose monitor;historical data relating to the glucose level of the user based off of the information received from the continuous glucose monitor;an estimate of the amount of un-metabolized insulin remaining in the user's body; anda bolus delivery object selectable to initiate a programming of a bolus delivery of insulin,wherein the processor is configured to display the startup screen in a locked configuration with at least one of the current glucose level, the historical data and the estimate of the amount of un-metabolized insulin in the user's body visible but not touch-selectable on the startup screen in the locked configuration to enable the user to assess whether any action needs to be taken with the portable insulin pump while the startup screen is in the locked configuration, and wherein the bolus delivery object on the startup screen is not selectable to initiate programming of a bolus delivery of insulin until the startup screen is unlocked from the locked configuration.
  • 12. The portable insulin pump system of claim 11, wherein the processor is further configured to display one or more unlock indicators on the startup screen and receive user input via the unlock indicators to unlock the startup screen from the locked configuration.
  • 13. The portable insulin pump system of claim 12, wherein the processor is further configured to display the unlock indicators over the startup screen such that at least a portion of the startup screen is visible.
  • 14. The portable insulin pump system of claim 11, wherein the historical data is presented in a graphical format illustrating glucose levels of the user over time.
  • 15. The portable insulin pump system of claim 14, wherein the startup screen further includes a timeframe object that is selectable to modify the timeframe over which the historical data is displayed, and the processor is further configured to display the historical data over the modified timeframe upon a subsequent activation of the startup screen.
  • 16. The portable insulin pump system of claim 11, further comprising a battery that powers the processor and a reservoir that contains insulin for delivery to the user, and the startup screen further includes at least one of a battery life indicator indicating a remaining life of the battery and a reservoir level indicator indicating a remaining amount of insulin in the reservoir.
  • 17. The portable insulin pump system of claim 11, wherein activating the graphical user interface from an inactive condition includes activating the graphical user interface from a sleep mode.
  • 18. The portable insulin pump system of claim 11, wherein the processor is further configured to display the startup screen when no commands have been entered into the graphical user interface for a predetermined period of time.
  • 19. The portable insulin pump system of claim 11, further comprising a portable insulin pump, and wherein the graphical user interface is part of the portable insulin pump.
  • 20. The portable insulin pump system of claim 11, further comprising a remote commander configured to control a portable insulin pump and the graphical user interface is part of the remote commander.
RELATED APPLICATIONS

This application is a continuation of application Ser. No. 15/072,408 filed Mar. 17, 2016, which is a continuation of application Ser. No. 13/800,453 filed Mar. 13, 2013, now U.S. Pat. No. 10,357,606 issued Jul. 23, 2019, each of which is hereby fully incorporated herein by reference.

US Referenced Citations (803)
Number Name Date Kind
2462596 Bent Feb 1949 A
2629376 Pierre et al. Feb 1953 A
2691542 Chenoweth Oct 1954 A
3059639 Blackman et al. Oct 1962 A
4393365 Kondo et al. Jul 1983 A
4443218 DeCant, Jr. et al. Apr 1984 A
4475901 Kraegen et al. Oct 1984 A
4634426 Kamen Jan 1987 A
5000664 Lawless et al. Mar 1991 A
5050612 Matsumura Sep 1991 A
5104374 Bishko Apr 1992 A
5122362 Phillips et al. Jun 1992 A
5148154 MacKay et al. Sep 1992 A
5153827 Coutre et al. Oct 1992 A
5181910 Scanlon Jan 1993 A
5207642 Orkin et al. May 1993 A
5219330 Bollish et al. Jun 1993 A
5224492 Takahashi et al. Jul 1993 A
5254096 Rondelet et al. Oct 1993 A
5295967 Rondelet et al. Mar 1994 A
5311175 Waldman May 1994 A
5338157 Blomquist Aug 1994 A
5339393 Duffy et al. Aug 1994 A
5364346 Schrezenmeir Nov 1994 A
5368562 Blomquist et al. Nov 1994 A
5376070 Purvis et al. Dec 1994 A
5389078 Zalesky et al. Feb 1995 A
5395326 Haber et al. Mar 1995 A
5438510 Bryant et al. Aug 1995 A
5485408 Blomquist Jan 1996 A
5569186 Lord et al. Oct 1996 A
5658250 Blomquist et al. Aug 1997 A
5658252 Johnson Aug 1997 A
5665065 Colman et al. Sep 1997 A
5669877 Blomquist Sep 1997 A
5674240 Bonutti et al. Oct 1997 A
5681285 Ford et al. Oct 1997 A
5685844 Marttila Nov 1997 A
5695473 Olsen Dec 1997 A
5713856 Eggers et al. Feb 1998 A
5782805 Meinzer et al. Jul 1998 A
5810771 Blomquist Sep 1998 A
5814015 Gargano Sep 1998 A
5822715 Worthington et al. Oct 1998 A
5839356 Dornbush et al. Nov 1998 A
5876370 Blomquist Mar 1999 A
5879143 Cote et al. Mar 1999 A
5885211 Eppstein et al. Mar 1999 A
5935099 Peterson et al. Aug 1999 A
5935106 Olsen Aug 1999 A
6023629 Tamada Feb 2000 A
6024539 Blomquist Feb 2000 A
6040834 Jain et al. Mar 2000 A
6077055 Vilks Jun 2000 A
6122536 Sun et al. Sep 2000 A
6142939 Eppstein et al. Nov 2000 A
6175752 Say et al. Jan 2001 B1
6225999 Jain et al. May 2001 B1
6229584 Chuo et al. May 2001 B1
6233471 Berner et al. May 2001 B1
6241704 Peterson et al. Jun 2001 B1
6248057 Mavity et al. Jun 2001 B1
6248067 Causey, III et al. Jun 2001 B1
6249717 Nicholson et al. Jun 2001 B1
6255781 Tsumura Jul 2001 B1
6269340 Ford et al. Jul 2001 B1
6272364 Kurnik Aug 2001 B1
6289248 Conley et al. Sep 2001 B1
6298254 Tamada Oct 2001 B2
D454574 Wasko et al. Mar 2002 S
6368272 Porumbescu Apr 2002 B1
6422057 Anderson Jul 2002 B1
6475180 Peterson et al. Nov 2002 B2
6517482 Elden et al. Feb 2003 B1
6540996 Zwaal et al. Apr 2003 B1
6544212 Galley et al. Apr 2003 B2
6546269 Kurnik Apr 2003 B1
6551276 Mann et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6562001 Lebel et al. May 2003 B2
6571128 Lebel et al. May 2003 B2
6577323 Jamieson et al. Jun 2003 B1
6577899 Lebel et al. Jun 2003 B2
6582366 Porumbescu Jun 2003 B1
6595919 Berner et al. Jul 2003 B2
6635014 Starkweather et al. Oct 2003 B2
6641533 Causey, III et al. Nov 2003 B2
6648821 Lebel et al. Nov 2003 B2
6668196 Villegas et al. Dec 2003 B1
6687522 Tamada Feb 2004 B2
6694191 Starkweather et al. Feb 2004 B2
6710051 Trier Mar 2004 B1
6740072 Starkweather et al. May 2004 B2
6740075 Lebel et al. May 2004 B2
6744350 Blomquist Jun 2004 B2
6771250 Oh Aug 2004 B1
6773412 O'Mahony et al. Aug 2004 B2
6790198 White et al. Sep 2004 B1
6809653 Mann et al. Oct 2004 B1
6810290 Lebel et al. Oct 2004 B2
6835175 Porumbescu Dec 2004 B1
6852104 Blomquist Feb 2005 B2
6872200 Mann et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6902905 Burson et al. Jun 2005 B2
6916159 Rush et al. Jul 2005 B2
6934220 Cruitt et al. Aug 2005 B1
6936029 Mann et al. Aug 2005 B2
6958705 Lebel et al. Oct 2005 B2
6974437 Lebel et al. Dec 2005 B2
6979326 Mann et al. Dec 2005 B2
6997905 Gillespie, Jr. et al. Feb 2006 B2
6997920 Mann et al. Feb 2006 B2
6998387 Goke et al. Feb 2006 B1
7025743 Mann et al. Apr 2006 B2
7033338 Vilks et al. Apr 2006 B2
7033539 Krensky et al. Apr 2006 B2
D521521 Jewitt et al. May 2006 S
7041082 Blomquist et al. May 2006 B2
7098803 Mann et al. Aug 2006 B2
7109878 Mann et al. Sep 2006 B2
D531637 Chotai et al. Nov 2006 S
7179226 Crothall et al. Feb 2007 B2
7183068 Burson et al. Feb 2007 B2
7204823 Estes et al. Apr 2007 B2
7231263 Choi Jun 2007 B2
7247428 Makrigiorgos Jul 2007 B2
7247702 Gardner et al. Jul 2007 B2
7248263 Freeman et al. Jul 2007 B2
7267665 Steil et al. Sep 2007 B2
7278983 Ireland et al. Oct 2007 B2
7291107 Hellwig et al. Nov 2007 B2
7295867 Berner et al. Nov 2007 B2
D557272 Glaser et al. Dec 2007 S
7307245 Faries, Jr. et al. Dec 2007 B2
7324012 Mann et al. Jan 2008 B2
7341577 Gill Mar 2008 B2
7344500 Talbot et al. Mar 2008 B2
7350190 Torres et al. Mar 2008 B2
7404796 Ginsberg Jul 2008 B2
7410475 Krensky et al. Aug 2008 B2
7446091 Van Den Berghe Nov 2008 B2
7464010 Yang et al. Dec 2008 B2
7471994 Ford et al. Dec 2008 B2
7491187 Van Den Berghe et al. Feb 2009 B2
7497827 Brister et al. Mar 2009 B2
7515060 Blomquist Apr 2009 B2
7553281 Hellwig et al. Jun 2009 B2
7559926 Blischak Jul 2009 B1
7591801 Brauker et al. Sep 2009 B2
7647237 Malave et al. Jan 2010 B2
7651489 Estes et al. Jan 2010 B2
7674485 Bhaskaran et al. Mar 2010 B2
7678071 Lebel et al. Mar 2010 B2
7678762 Green et al. Mar 2010 B2
7678763 Green et al. Mar 2010 B2
7711402 Shults et al. May 2010 B2
7715893 Kamath et al. May 2010 B2
7717903 Estes et al. May 2010 B2
7727148 Talbot et al. Jun 2010 B2
7734323 Blomquist et al. Jun 2010 B2
7751907 Blomquist Jul 2010 B2
7766829 Sloan et al. Aug 2010 B2
7768386 Hayter et al. Aug 2010 B2
7768408 Reggiardo et al. Aug 2010 B2
7774145 Brauker et al. Aug 2010 B2
7785313 Mastrototaro Aug 2010 B2
7801582 Peyser Sep 2010 B2
7806886 Kanderian, Jr. et al. Oct 2010 B2
7831287 Brister et al. Nov 2010 B2
7831310 Lebel et al. Nov 2010 B2
7837647 Estes et al. Nov 2010 B2
7869851 Hellwig et al. Jan 2011 B2
7875022 Wenger et al. Jan 2011 B2
7877703 Fleming Jan 2011 B1
7884729 Reggiardo et al. Feb 2011 B2
7912674 Killoren Clark et al. Mar 2011 B2
7920907 McGarraugh et al. Apr 2011 B2
7935105 Miller et al. May 2011 B2
7941200 Weinert et al. May 2011 B2
7942844 Moberg et al. May 2011 B2
7945452 Fathallah et al. May 2011 B2
7946985 Mastrototaro et al. May 2011 B2
7951114 Rush et al. May 2011 B2
7967773 Amborn et al. Jun 2011 B2
7972296 Braig et al. Jul 2011 B2
7976492 Brauker et al. Jul 2011 B2
7979136 Young et al. Jul 2011 B2
7985330 Wang et al. Jul 2011 B2
7988850 Roncadi et al. Aug 2011 B2
7996158 Hayter et al. Aug 2011 B2
8005524 Brauker Aug 2011 B2
8012119 Estes et al. Sep 2011 B2
8032226 Miller et al. Oct 2011 B2
8062249 Wilinska et al. Nov 2011 B2
8066665 Rush et al. Nov 2011 B2
8075527 Rush et al. Dec 2011 B2
8078983 Davis et al. Dec 2011 B2
8079983 Rush et al. Dec 2011 B2
8079984 Rush et al. Dec 2011 B2
8083718 Rush et al. Dec 2011 B2
8088098 Yodfat et al. Jan 2012 B2
8093212 Gardner et al. Jan 2012 B2
8109921 Estes et al. Feb 2012 B2
8114066 Naef et al. Feb 2012 B2
8114350 Silver et al. Feb 2012 B1
8119593 Richardson et al. Feb 2012 B2
8121689 Kalgren et al. Feb 2012 B2
8127046 Grant et al. Feb 2012 B2
8129429 Sporn et al. Mar 2012 B2
8133178 Brauker et al. Mar 2012 B2
8133197 Blomquist et al. Mar 2012 B2
8140312 Hayter et al. Mar 2012 B2
8147446 Yodfat et al. Apr 2012 B2
8152789 Starkweather et al. Apr 2012 B2
D660317 Jesberger May 2012 S
8192394 Estes et al. Jun 2012 B2
8204729 Sher Jun 2012 B2
8208984 Blomquist et al. Jun 2012 B2
8211093 Miller et al. Jul 2012 B2
8219222 Blomquist Jul 2012 B2
8221345 Blomquist Jul 2012 B2
8234128 Martucci et al. Jul 2012 B2
D664982 Rai et al. Aug 2012 S
D665407 Bitran et al. Aug 2012 S
8237715 Buck et al. Aug 2012 B2
8246540 Ginsberg Aug 2012 B2
8250483 Blomquist Aug 2012 B2
8251906 Brauker et al. Aug 2012 B2
D667022 LoBosco et al. Sep 2012 S
D667841 Rai et al. Sep 2012 S
8257259 Brauker et al. Sep 2012 B2
8257300 Budiman et al. Sep 2012 B2
8287495 Michaud et al. Oct 2012 B2
8287514 Miller et al. Oct 2012 B2
D671125 Hansen et al. Nov 2012 S
8310415 McLaughlin et al. Nov 2012 B2
8311749 Brauker et al. Nov 2012 B2
8317752 Cozmi et al. Nov 2012 B2
8337469 Eberhart et al. Dec 2012 B2
8344847 Moberg et al. Jan 2013 B2
8348885 Moberg et al. Jan 2013 B2
8369919 Kamath et al. Feb 2013 B2
8372040 Huang et al. Feb 2013 B2
8395581 Graskov et al. Mar 2013 B2
8402145 Holden et al. Mar 2013 B2
8414563 Kamen et al. Apr 2013 B2
8452413 Young May 2013 B2
8454510 Yodfat et al. Jun 2013 B2
8454576 Mastrototaro et al. Jun 2013 B2
8460231 Brauker et al. Jun 2013 B2
D691632 Impas Oct 2013 S
8552880 Kopp et al. Oct 2013 B2
8562558 Kamath et al. Oct 2013 B2
D694252 Helm Nov 2013 S
D694253 Helm Nov 2013 S
8573027 Rosinko et al. Nov 2013 B2
8601561 Cleron Dec 2013 B1
8650937 Brown Feb 2014 B2
8657779 Blomquist Feb 2014 B2
8710993 Hayter et al. Apr 2014 B2
8712748 Thukral et al. Apr 2014 B2
D705798 Lim et al. May 2014 S
D707705 Folken et al. Jun 2014 S
8777895 Hsu Jul 2014 B2
8818782 Thukral Aug 2014 B2
D712920 Sloo et al. Sep 2014 S
D715315 Wood Oct 2014 S
8882701 DeBelser et al. Nov 2014 B2
8929823 Mears et al. Jan 2015 B2
8938306 Lebel et al. Jan 2015 B2
8985253 Winter et al. Mar 2015 B2
8986253 DiPerna Mar 2015 B2
D727337 Kim et al. Apr 2015 S
9008803 Blomquist Apr 2015 B2
9037254 John May 2015 B2
D731529 Cavander et al. Jun 2015 S
D739872 Bang et al. Sep 2015 S
D745020 Mariet et al. Dec 2015 S
D746849 Anzures et al. Jan 2016 S
9238100 Kruse et al. Jan 2016 B2
D748644 Huang Feb 2016 S
D754181 Dong et al. Apr 2016 S
D754690 Park et al. Apr 2016 S
D755223 Liu et al. May 2016 S
D757032 Sabia et al. May 2016 S
9335910 Farnan et al. May 2016 B2
D759687 Chang et al. Jun 2016 S
9364679 John Jun 2016 B2
D761843 Kim Jul 2016 S
9381297 Brown Jul 2016 B2
9381302 Miller Jul 2016 B2
9400241 Brown Jul 2016 B2
D763267 Brunner et al. Aug 2016 S
D765099 Kim et al. Aug 2016 S
D766940 Napper et al. Sep 2016 S
D767605 Mensinger et al. Sep 2016 S
D770519 Kobetz et al. Nov 2016 S
D771086 Kim et al. Nov 2016 S
D771650 Yang Nov 2016 S
D771690 Yin et al. Nov 2016 S
9483615 Roberts Nov 2016 B2
9486171 Saint Nov 2016 B2
9486578 Finan et al. Nov 2016 B2
D773534 Yuk et al. Dec 2016 S
D774078 Kisselev et al. Dec 2016 S
D775184 Song et al. Dec 2016 S
D779505 Cabrera, Jr. et al. Feb 2017 S
D780199 Croan Feb 2017 S
D784401 Joi Apr 2017 S
D789417 Yamasaki et al. Jun 2017 S
D789968 Mensinger et al. Jun 2017 S
9669160 Harris Jun 2017 B2
9675756 Kamen Jun 2017 B2
9715327 Rosinko et al. Jul 2017 B2
D794650 Lee et al. Aug 2017 S
D798895 Kim et al. Oct 2017 S
9814835 Kruse et al. Nov 2017 B2
9833177 Blomquist Dec 2017 B2
D808990 Ayvazian et al. Jan 2018 S
D808998 Wu et al. Jan 2018 S
9867937 Saint et al. Jan 2018 B2
9867953 Rosinko Jan 2018 B2
9942091 Harvey et al. Apr 2018 B2
9970893 Morgan May 2018 B2
9974903 Davis et al. May 2018 B1
D820283 Cabrera, Jr. et al. Jun 2018 S
D820302 Choi et al. Jun 2018 S
D822695 Iketsuki et al. Jul 2018 S
10016561 Saint et al. Jul 2018 B2
10035065 Schupak et al. Jul 2018 B2
10052049 Blomquist et al. Aug 2018 B2
D831049 Agarwal et al. Oct 2018 S
D834594 Anzures et al. Nov 2018 S
D836131 Apodaca et al. Dec 2018 S
10213547 Rosinko Feb 2019 B2
D844643 Cabrera, Jr. et al. Apr 2019 S
D847147 Wesley et al. Apr 2019 S
D847169 Sombreireiro et al. Apr 2019 S
D849036 Fuller et al. May 2019 S
D851112 Papolu et al. Jun 2019 S
D852809 Rad et al. Jul 2019 S
D852811 Babion Jul 2019 S
D853423 Zimmerman et al. Jul 2019 S
10357606 Rosinko et al. Jul 2019 B2
10357607 Blomquist et al. Jul 2019 B2
D858535 Evans et al. Sep 2019 S
D862491 Janicki Oct 2019 S
D864217 Farnan et al. Oct 2019 S
D864218 Farnan et al. Oct 2019 S
D864219 Farnan et al. Oct 2019 S
10430043 Rosinko et al. Oct 2019 B2
10434253 Diperna et al. Oct 2019 B2
D865778 Kim et al. Nov 2019 S
D866566 Chang et al. Nov 2019 S
10549051 Rosinko Feb 2020 B2
10569016 Rosinko Feb 2020 B2
D877166 Dieken et al. Mar 2020 S
10653834 Kruse et al. May 2020 B2
D896271 Levy et al. Sep 2020 S
D896819 Joseph Sep 2020 S
D899455 Rondoni et al. Oct 2020 S
10864322 Saint et al. Dec 2020 B2
11452815 Kamen Sep 2022 B2
20010001144 Kapp May 2001 A1
20010027791 Wallace Oct 2001 A1
20010031944 Peterson et al. Oct 2001 A1
20010037217 Abensour et al. Nov 2001 A1
20010041831 Starkweather et al. Nov 2001 A1
20020002326 Causey, III et al. Jan 2002 A1
20020016568 Lebel Feb 2002 A1
20020019606 Lebel Feb 2002 A1
20020065454 Lebel et al. May 2002 A1
20020072932 Swamy Jun 2002 A1
20020077852 Ford et al. Jun 2002 A1
20020107476 Mann et al. Aug 2002 A1
20020143580 Bristol et al. Oct 2002 A1
20020183693 Peterson et al. Dec 2002 A1
20020193679 Malave et al. Dec 2002 A1
20030032867 Crothall et al. Feb 2003 A1
20030036683 Kehr et al. Feb 2003 A1
20030050621 Lebel et al. Mar 2003 A1
20030060765 Campbell et al. Mar 2003 A1
20030065308 Lebel et al. Apr 2003 A1
20030114836 Estes et al. Jun 2003 A1
20030130616 Steil et al. Jul 2003 A1
20030145854 Hickle Aug 2003 A1
20030159945 Miyazaki et al. Aug 2003 A1
20030160683 Blomquist Aug 2003 A1
20030161744 Vilks et al. Aug 2003 A1
20030163088 Blomquist Aug 2003 A1
20030163090 Blomquist et al. Aug 2003 A1
20030163789 Blomquist Aug 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030212364 Mann et al. Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20030236489 Jacobson et al. Dec 2003 A1
20040015102 Cummings et al. Jan 2004 A1
20040015132 Brown Jan 2004 A1
20040068230 Estes et al. Apr 2004 A1
20040073095 Causey, III et al. Apr 2004 A1
20040115067 Rush et al. Jun 2004 A1
20040122353 Shahmirian et al. Jun 2004 A1
20040152622 Keith et al. Aug 2004 A1
20040172222 Simpson Sep 2004 A1
20040180810 Pilarski Sep 2004 A1
20040193025 Steil et al. Sep 2004 A1
20040193090 Lebel et al. Sep 2004 A1
20040225252 Gillespie et al. Nov 2004 A1
20040254434 Goodnow et al. Dec 2004 A1
20050021006 Tonnies Jan 2005 A1
20050022274 Campbell et al. Jan 2005 A1
20050027182 Siddiqui et al. Feb 2005 A1
20050030164 Blomquist Feb 2005 A1
20050065464 Talbot et al. Mar 2005 A1
20050065760 Murtfeldt et al. Mar 2005 A1
20050081847 Lee et al. Apr 2005 A1
20050095063 Fathallah et al. May 2005 A1
20050137530 Campbell et al. Jun 2005 A1
20050143864 Blomquist Jun 2005 A1
20050171513 Mann et al. Aug 2005 A1
20050182358 Veit et al. Aug 2005 A1
20050182831 Uchida et al. Aug 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20050197553 Cooper Sep 2005 A1
20050197621 Poulsen et al. Sep 2005 A1
20050228234 Yang Oct 2005 A1
20050272640 Doyle, III et al. Dec 2005 A1
20050277872 Colby, Jr. et al. Dec 2005 A1
20050277912 John Dec 2005 A1
20060001538 Kraft et al. Jan 2006 A1
20060001550 Mann et al. Jan 2006 A1
20060014670 Green et al. Jan 2006 A1
20060031094 Cohen et al. Feb 2006 A1
20060047192 Hellwig et al. Mar 2006 A1
20060047538 Condurso et al. Mar 2006 A1
20060073891 Holt Apr 2006 A1
20060080059 Stupp et al. Apr 2006 A1
20060085223 Anderson et al. Apr 2006 A1
20060094985 Aceti et al. May 2006 A1
20060122577 Poulsen et al. Jun 2006 A1
20060132292 Blomquist Jun 2006 A1
20060137695 Hellwig et al. Jun 2006 A1
20060167345 Vespasiani Jul 2006 A1
20060173406 Hayes et al. Aug 2006 A1
20060173444 Choy et al. Aug 2006 A1
20060202859 Mastrototaro et al. Sep 2006 A1
20060224109 Steil et al. Oct 2006 A1
20060229557 Fathallah Oct 2006 A1
20060253097 Braig et al. Nov 2006 A1
20060264895 Flanders Nov 2006 A1
20060271020 Huang et al. Nov 2006 A1
20060272652 Stocker et al. Dec 2006 A1
20060276771 Galley et al. Dec 2006 A1
20070016127 Staib et al. Jan 2007 A1
20070021733 Hansen et al. Jan 2007 A1
20070033074 Nitzan et al. Feb 2007 A1
20070060796 Kim Mar 2007 A1
20070060871 Istoc et al. Mar 2007 A1
20070060874 Nesbitt et al. Mar 2007 A1
20070066956 Finkel Mar 2007 A1
20070083152 Williams, Jr. et al. Apr 2007 A1
20070083335 Moerman Apr 2007 A1
20070093786 Goldsmith et al. Apr 2007 A1
20070100222 Mastrototaro et al. May 2007 A1
20070106135 Sloan et al. May 2007 A1
20070112298 Mueller, Jr. et al. May 2007 A1
20070112299 Smit et al. May 2007 A1
20070118405 Campbell et al. May 2007 A1
20070124002 Estes et al. May 2007 A1
20070149861 Crothall et al. Jun 2007 A1
20070156033 Causey, III et al. Jul 2007 A1
20070156457 Brown Jul 2007 A1
20070173712 Shah et al. Jul 2007 A1
20070203454 Shermer et al. Aug 2007 A1
20070213657 Jennewine et al. Sep 2007 A1
20070233051 Hohl et al. Oct 2007 A1
20070245258 Ginggen et al. Oct 2007 A1
20070251835 Mehta et al. Nov 2007 A1
20070253021 Mehta et al. Nov 2007 A1
20070253380 Jollota et al. Nov 2007 A1
20070254593 Jollota et al. Nov 2007 A1
20070255116 Mehta et al. Nov 2007 A1
20070255125 Moberg et al. Nov 2007 A1
20070255126 Moberg et al. Nov 2007 A1
20070255250 Moberg et al. Nov 2007 A1
20070255348 Holtzclaw Nov 2007 A1
20070258395 Jollota et al. Nov 2007 A1
20070287985 Estes et al. Dec 2007 A1
20070299389 Halbert et al. Dec 2007 A1
20080004601 Jennewine et al. Jan 2008 A1
20080030369 Mann et al. Feb 2008 A1
20080033357 Mann et al. Feb 2008 A1
20080033360 Evans et al. Feb 2008 A1
20080033361 Evans et al. Feb 2008 A1
20080051709 Mounce et al. Feb 2008 A1
20080051714 Moberg et al. Feb 2008 A1
20080051716 Stutz Feb 2008 A1
20080059158 Matsuo et al. Mar 2008 A1
20080065007 Peterson et al. Mar 2008 A1
20080065016 Peterson et al. Mar 2008 A1
20080071209 Moubayed et al. Mar 2008 A1
20080071210 Moubayed et al. Mar 2008 A1
20080071217 Moubayed et al. Mar 2008 A1
20080071251 Moubayed et al. Mar 2008 A1
20080071580 Marcus et al. Mar 2008 A1
20080076969 Kraft et al. Mar 2008 A1
20080097289 Steil et al. Apr 2008 A1
20080106431 Blomquist May 2008 A1
20080114299 Damgaard-Sorensen et al. May 2008 A1
20080132844 Peterson et al. Jun 2008 A1
20080139907 Rao et al. Jun 2008 A1
20080147004 Mann et al. Jun 2008 A1
20080147050 Mann et al. Jun 2008 A1
20080148235 Foresti et al. Jun 2008 A1
20080154513 Kovatchev et al. Jun 2008 A1
20080156661 Cooper et al. Jul 2008 A1
20080171697 Jacotot et al. Jul 2008 A1
20080171967 Blomquist et al. Jul 2008 A1
20080172026 Blomquist Jul 2008 A1
20080172027 Blomquist Jul 2008 A1
20080172028 Blomquist Jul 2008 A1
20080172029 Blomquist Jul 2008 A1
20080172030 Blomquist Jul 2008 A1
20080172031 Blomquist Jul 2008 A1
20080177165 Blomquist et al. Jul 2008 A1
20080200868 Alberti et al. Aug 2008 A1
20080206799 Blomquist Aug 2008 A1
20080228056 Blomquist et al. Sep 2008 A1
20080249470 Malave et al. Oct 2008 A1
20080255438 Saidara et al. Oct 2008 A1
20080255517 Nair et al. Oct 2008 A1
20080269585 Ginsberg Oct 2008 A1
20080269714 Mastrototaro et al. Oct 2008 A1
20080269723 Mastrototaro et al. Oct 2008 A1
20080287761 Hayter Nov 2008 A1
20080287922 Panduro Nov 2008 A1
20080288115 Rusnak et al. Nov 2008 A1
20080294024 Cosentino et al. Nov 2008 A1
20080294142 Patel et al. Nov 2008 A1
20080294294 Blomquist Nov 2008 A1
20080300534 Blomquist Dec 2008 A1
20080300572 Rankers et al. Dec 2008 A1
20080306434 Dobbles et al. Dec 2008 A1
20080306444 Brister et al. Dec 2008 A1
20080312584 Montgomery et al. Dec 2008 A1
20080312585 Brukalo et al. Dec 2008 A1
20090006061 Thukral Jan 2009 A1
20090006129 Thukral et al. Jan 2009 A1
20090018495 Panduro Jan 2009 A1
20090058598 Sanchez Sanchez Mar 2009 A1
20090069745 Estes et al. Mar 2009 A1
20090069746 Miller et al. Mar 2009 A1
20090069749 Miller et al. Mar 2009 A1
20090069785 Miller et al. Mar 2009 A1
20090069787 Estes et al. Mar 2009 A1
20090088731 Campbell et al. Apr 2009 A1
20090093756 Minaie et al. Apr 2009 A1
20090099866 Newman Apr 2009 A1
20090099867 Newman Apr 2009 A1
20090105636 Hayter et al. Apr 2009 A1
20090105646 Hendrixson et al. Apr 2009 A1
20090113295 Halpern et al. Apr 2009 A1
20090131860 Nielsen May 2009 A1
20090150484 Roberts Jun 2009 A1
20090156990 Wenger et al. Jun 2009 A1
20090156991 Roberts Jun 2009 A1
20090157202 Roberts et al. Jun 2009 A1
20090157622 Roberts et al. Jun 2009 A1
20090157695 Roberts Jun 2009 A1
20090158274 Roberts Jun 2009 A1
20090163855 Shin et al. Jun 2009 A1
20090167717 Wang et al. Jul 2009 A1
20090171269 Jennewine et al. Jul 2009 A1
20090177142 Blomquist et al. Jul 2009 A1
20090177147 Blomquist et al. Jul 2009 A1
20090177154 Blomquist Jul 2009 A1
20090177180 Rubalcaba, Jr. et al. Jul 2009 A1
20090177248 Roberts Jul 2009 A1
20090177249 Roberts et al. Jul 2009 A1
20090177769 Roberts Jul 2009 A1
20090177991 Davis et al. Jul 2009 A1
20090192366 Mensinger et al. Jul 2009 A1
20090192724 Brauker et al. Jul 2009 A1
20090192745 Kamath et al. Jul 2009 A1
20090204341 Brauker et al. Aug 2009 A1
20090212966 Panduro Aug 2009 A1
20090216100 Ebner et al. Aug 2009 A1
20090221890 Saffer Sep 2009 A1
20090240193 Mensinger et al. Sep 2009 A1
20090247931 Damgaard-Sorensen Oct 2009 A1
20090247982 Krulevitch et al. Oct 2009 A1
20090254037 Bryant, Jr. et al. Oct 2009 A1
20090270833 DeBelser et al. Oct 2009 A1
20090275886 Blomquist et al. Nov 2009 A1
20090281393 Smith Nov 2009 A1
20100008795 DiPerna Jan 2010 A1
20100010330 Rankers et al. Jan 2010 A1
20100010647 Schroeder et al. Jan 2010 A1
20100030045 Gottlieb et al. Feb 2010 A1
20100030387 Sen Feb 2010 A1
20100057043 Kovatchev et al. Mar 2010 A1
20100069730 Bergstrom et al. Mar 2010 A1
20100069890 Graskov et al. Mar 2010 A1
20100081993 O'Connor Apr 2010 A1
20100094110 Heller et al. Apr 2010 A1
20100095229 Dixon et al. Apr 2010 A1
20100100037 Cozmi et al. Apr 2010 A1
20100105999 Dixon et al. Apr 2010 A1
20100107103 Wallaert Apr 2010 A1
20100121169 Petisce et al. May 2010 A1
20100121170 Rule May 2010 A1
20100125241 Prud'Homme et al. May 2010 A1
20100130933 Holland et al. May 2010 A1
20100138197 Sher Jun 2010 A1
20100145276 Yodfat et al. Jun 2010 A1
20100164727 Bazargan et al. Jul 2010 A1
20100168711 Bazargan et al. Jul 2010 A1
20100174266 Estes Jul 2010 A1
20100174553 Kaufman et al. Jul 2010 A1
20100179402 Goode, Jr. et al. Jul 2010 A1
20100185142 Kamen et al. Jul 2010 A1
20100185175 Kamen et al. Jul 2010 A1
20100198034 Thomas et al. Aug 2010 A1
20100198142 Sloan et al. Aug 2010 A1
20100198183 Lanigan et al. Aug 2010 A1
20100222765 Blomquist et al. Sep 2010 A1
20100228186 Estes et al. Sep 2010 A1
20100234707 Goode, Jr. et al. Sep 2010 A1
20100253768 El-Maraghi et al. Oct 2010 A1
20100261987 Kamath et al. Oct 2010 A1
20100262117 Magni et al. Oct 2010 A1
20100262434 Shaya Oct 2010 A1
20100274592 Nitzan et al. Oct 2010 A1
20100274751 Blomquist Oct 2010 A1
20100286601 Yodfat et al. Nov 2010 A1
20100292634 Kircher, Jr. et al. Nov 2010 A1
20100295686 Sloan et al. Nov 2010 A1
20100298685 Hayter et al. Nov 2010 A1
20100305421 Ow-Wing Dec 2010 A1
20100312085 Andrews et al. Dec 2010 A1
20100317950 Galley et al. Dec 2010 A1
20100323431 Rutkowski et al. Dec 2010 A1
20100324382 Cantwell et al. Dec 2010 A1
20100324398 Tzyy-Ping Dec 2010 A1
20100331651 Groll Dec 2010 A1
20110006876 Moberg et al. Jan 2011 A1
20110009725 Hill et al. Jan 2011 A1
20110009813 Rankers Jan 2011 A1
20110015509 Peyser Jan 2011 A1
20110040247 Mandro et al. Feb 2011 A1
20110040251 Blomquist et al. Feb 2011 A1
20110047499 Mandro et al. Feb 2011 A1
20110053121 Heaton Mar 2011 A1
20110054390 Searle et al. Mar 2011 A1
20110054391 Ward et al. Mar 2011 A1
20110056264 Kaplan et al. Mar 2011 A1
20110058485 Sloan Mar 2011 A1
20110071765 Yodfat et al. Mar 2011 A1
20110082439 Wenger et al. Apr 2011 A1
20110092788 Long et al. Apr 2011 A1
20110098548 Budiman et al. Apr 2011 A1
20110098637 Hill Apr 2011 A1
20110106011 Cinar et al. May 2011 A1
20110106050 Yodfat et al. May 2011 A1
20110112478 Gregor et al. May 2011 A1
20110112505 Starkweather et al. May 2011 A1
20110112506 Starkweather et al. May 2011 A1
20110118699 Yodfat et al. May 2011 A1
20110124996 Reinke et al. May 2011 A1
20110125095 Lebel et al. May 2011 A1
20110130746 Budiman Jun 2011 A1
20110137239 Debelser et al. Jun 2011 A1
20110144569 Britton et al. Jun 2011 A1
20110144586 Michaud et al. Jun 2011 A1
20110152770 Diperna et al. Jun 2011 A1
20110166875 Hayter et al. Jul 2011 A1
20110178462 Moberg et al. Jul 2011 A1
20110178717 Goodnow et al. Jul 2011 A1
20110184342 Pesach et al. Jul 2011 A1
20110190694 Lanier, Jr. et al. Aug 2011 A1
20110193704 Harper et al. Aug 2011 A1
20110196213 Thukral et al. Aug 2011 A1
20110201911 Johnson et al. Aug 2011 A1
20110208155 Palerm et al. Aug 2011 A1
20110213225 Bernstein et al. Sep 2011 A1
20110256848 Bok, II Oct 2011 A1
20110257895 Brauker et al. Oct 2011 A1
20110266999 Yodfat et al. Nov 2011 A1
20110320130 Valdes et al. Dec 2011 A1
20120013625 Blomquist et al. Jan 2012 A1
20120013802 Blomquist et al. Jan 2012 A1
20120019559 Siler et al. Jan 2012 A1
20120029708 Miller et al. Feb 2012 A1
20120029941 Malave et al. Feb 2012 A1
20120030610 DiPerna et al. Feb 2012 A1
20120041415 Estes et al. Feb 2012 A1
20120053522 Yodfat et al. Mar 2012 A1
20120059353 Kovatchev et al. Mar 2012 A1
20120084728 Huang et al. Apr 2012 A1
20120095315 Tenbarge et al. Apr 2012 A1
20120096451 Tenbarge et al. Apr 2012 A1
20120098868 Nagasaka Apr 2012 A1
20120123230 Brown et al. May 2012 A1
20120163481 Ebner et al. Jun 2012 A1
20120226124 Blomquist Sep 2012 A1
20120232484 Blomquist Sep 2012 A1
20120232485 Blomquist Sep 2012 A1
20120232520 Sloan et al. Sep 2012 A1
20120232521 Blomquist Sep 2012 A1
20120238852 Brauker et al. Sep 2012 A1
20120238854 Blomquist et al. Sep 2012 A1
20120239362 Blomquist Sep 2012 A1
20120245447 Karan et al. Sep 2012 A1
20120245524 Estes et al. Sep 2012 A1
20120265722 Blomquist Oct 2012 A1
20120296269 Blomquist Nov 2012 A1
20120330227 Budiman et al. Dec 2012 A1
20130012917 Miller et al. Jan 2013 A1
20130036377 Colley Feb 2013 A1
20130050106 Chung Feb 2013 A1
20130053816 DiPerna et al. Feb 2013 A1
20130131630 Blomquist May 2013 A1
20130151611 Graham et al. Jun 2013 A1
20130162426 Wiesner et al. Jun 2013 A1
20130172710 Mears Jul 2013 A1
20130191770 Bartz Jul 2013 A1
20130283196 Farnan Oct 2013 A1
20130298024 Rhee et al. Nov 2013 A1
20130324928 Kruse Dec 2013 A1
20130331790 Brown et al. Dec 2013 A1
20130332388 Martell et al. Dec 2013 A1
20130332874 Rosinko et al. Dec 2013 A1
20140012511 Mensinger et al. Jan 2014 A1
20140039455 Miller Feb 2014 A1
20140054883 Lanigan et al. Feb 2014 A1
20140066890 Sloan et al. Mar 2014 A1
20140074059 Howell et al. Mar 2014 A1
20140137641 Brown May 2014 A1
20140171772 Blomquist Jun 2014 A1
20140187890 Mensinger et al. Jul 2014 A1
20140188398 Cohen et al. Jul 2014 A1
20140200426 Taub et al. Jul 2014 A1
20140213977 Miller Jul 2014 A1
20140273042 Saint Sep 2014 A1
20140275419 Ward et al. Sep 2014 A1
20140276419 Rosinko et al. Sep 2014 A1
20140276420 Rosinko Sep 2014 A1
20140276556 Saint et al. Sep 2014 A1
20140276574 Saint Sep 2014 A1
20140300490 Kotz Oct 2014 A1
20140350371 Blomquist et al. Nov 2014 A1
20140374275 Morales et al. Dec 2014 A1
20140378898 Rosinko Dec 2014 A1
20150045641 Rule Feb 2015 A1
20150073337 Saint et al. Mar 2015 A1
20150089369 Ahn Mar 2015 A1
20150112264 Kamen Apr 2015 A1
20150174320 Grant Jun 2015 A1
20150177980 Yanase et al. Jun 2015 A1
20150205930 Shaanan et al. Jul 2015 A1
20150289823 Rack-Gomer et al. Oct 2015 A1
20150350861 Soli et al. Dec 2015 A1
20160030669 Harris et al. Feb 2016 A1
20160082188 Blomquist et al. Mar 2016 A1
20160098848 Zamanakos et al. Apr 2016 A1
20160103887 Fletcher et al. Apr 2016 A1
20160113594 Koehler et al. Apr 2016 A1
20160119210 Koehler et al. Apr 2016 A1
20160121047 Kruse et al. May 2016 A1
20160199571 Rosinko et al. Jul 2016 A1
20160228041 Heller et al. Aug 2016 A1
20160271325 Farnan Sep 2016 A1
20160328991 Simpson et al. Nov 2016 A1
20170000943 Blomquist et al. Jan 2017 A1
20170056590 DiPerna et al. Mar 2017 A1
20170134878 Loychik et al. May 2017 A1
20170181645 Mahalingam et al. Jun 2017 A1
20170216524 Haider et al. Aug 2017 A1
20170351842 Booth et al. Dec 2017 A1
20180021514 Rosinko Jan 2018 A1
20180042559 Cabrera, Jr. et al. Feb 2018 A1
20180092578 Blomquist Apr 2018 A1
20180137252 Mairs et al. May 2018 A1
20180137938 Vaddiraju et al. May 2018 A1
20180336208 Kim Nov 2018 A1
20180361060 Rosinko Dec 2018 A9
20190022314 Schmidt et al. Jan 2019 A1
20190121506 Matikyan Apr 2019 A1
20190125969 Montgomery et al. May 2019 A1
20190167902 Kamen et al. Jun 2019 A1
20190183434 Sjolund et al. Jun 2019 A1
20190259485 Blomquist et al. Aug 2019 A1
20190321552 Diperna et al. Oct 2019 A1
20190328967 Blomquist Oct 2019 A1
20190350501 Blomquist et al. Nov 2019 A1
20190365997 Harris Dec 2019 A1
20190388015 Blomquist Dec 2019 A1
20200012401 Rosinko et al. Jan 2020 A1
20200016335 Diperna et al. Jan 2020 A1
20200114076 Ulrich et al. Apr 2020 A1
Foreign Referenced Citations (47)
Number Date Country
101689226 Mar 2010 CN
399065 Jul 1924 DE
4407005 Mar 1995 DE
19819407 Nov 1999 DE
10121317 Nov 2002 DE
10352456 Jul 2005 DE
1102194 May 2001 EP
1571582 Sep 2005 EP
2006034323 Feb 2006 JP
WO-0045696 Aug 2000 WO
WO-0074753 Dec 2000 WO
WO-0152727 Jul 2001 WO
WO-02062212 Aug 2002 WO
WO-03082091 Oct 2003 WO
WO-2005046559 May 2005 WO
WO-2006061169 Jun 2006 WO
WO-2006127841 Nov 2006 WO
WO-2007000425 Jan 2007 WO
WO-2007056592 May 2007 WO
WO-2007089537 Aug 2007 WO
WO-2007149533 Dec 2007 WO
WO-2008048556 Apr 2008 WO
WO-2008048582 Apr 2008 WO
WO-2008048583 Apr 2008 WO
WO-2008048584 Apr 2008 WO
WO-2008048585 Apr 2008 WO
WO-2008048586 Apr 2008 WO
WO-2008048587 Apr 2008 WO
WO-2008082966 Jul 2008 WO
WO-2008091320 Jul 2008 WO
WO-2008112078 Sep 2008 WO
WO-2008153689 Dec 2008 WO
WO-2008153819 Dec 2008 WO
WO-2009016636 Feb 2009 WO
WO-2009032400 Mar 2009 WO
WO-2009035753 Mar 2009 WO
WO-2009035759 Mar 2009 WO
WO-2009035761 Mar 2009 WO
WO-2009035762 Mar 2009 WO
WO-2009088983 Jul 2009 WO
WO-2009089028 Jul 2009 WO
WO-2009089029 Jul 2009 WO
WO-2010111505 Sep 2010 WO
WO-2011014704 Feb 2011 WO
WO-2011068648 Jun 2011 WO
WO-2013016363 Jan 2013 WO
WO-2013184896 Dec 2013 WO
Non-Patent Literature Citations (46)
Entry
“Press Release: U.S. FDA Approves the Dexcom G4(TM) PLATINUM Continuous Glucose Monitor (CGM)”, Dow Jones Institutional News, Oct. 8, 2012 (Dow Jones & Co., Inc., New York, NY), from http://www.proquest.com/wire-feeds/press-release-u-s-fda-approves-dexcom-g4-tm/docview/2111039433/se-2?accountid=14753 (Year: 2012).
Dexcom SEVEN(TM) System Features, Dec. 4, 2008, The Wayback Machine—https://web.archive.org/web/20081204095723/http://www.dexcom.com:80/220-seven-system-features.aspx (Year: 2008).
Dexcom The SEVEN® System, Dec. 8, 2008, The Wayback Machine—https://web.archive.Org/web/20081208123339/http://www.dexcom.com:80/210-the-seven-system.aspx (Year: 2008).
Dexcom G4 User's Guide—Dexcom G4 Platinum Professional Continuous Glucose Monitoring System, 2014 (Year: 2014).
Dexcom G4 Platinum Continuous Glucose Monitoring System, Receiver with SHARE, Poster (Dexcom, Inc. I 6340 Sequence Drive I, San Diego, CA 92121 (2015) (Year: 2015).
Application and File History for U.S. Appl. No. 13/800,453, filed Mar. 13, 2013, Inventors Rosinko.
Application and File History for U.S. Appl. No. 15/072,408, filed Mar. 17, 2016, Inventors Rosinko, et al.
Ballinger B., “Do You Really Need 10,000 Steps a Day?,” May 30, 2016, retrieved from https://blog.cardiogr.am/do-you-really-need-10-000-steps-a-day-ce1c006b5d0a, on Jul. 18, 2019, 1 page.
Bott, et al., “Impact of Smoking on the Metabolic Action of Subcutaneous Regular Insulin in Type 2 Diabetic Patients,” Horm. Metab. Res., vol. 37, 2005, pp. 445-449.
Ceglys G., “Risk Assessment Report on Dribble,” Aug. 17, 2018, retrieved from https://dribbble.com/shots/4967551-Risk-Assessment-Report, on Jul. 26, 2019, 2 pages.
Chase, et at., “The Use of Insulin Pumps With Meal Bolus Alarms in Children With Type 1 Diabetes to Improve Glycemic Control,” Diabetes Carem, vol. 29, No. 5, May 2006, pp. 1012-1015.
“Compare Insulin Pump for Diabetes,” Printed from www.diabetesnet.com/diabetes-technology/insulin-pump-models.php, Jun. 18, 2009, 4 pages.
“Croissant, Pretzel and Bread Icons,” Apr. 27, 2017, retrieved from https://www.shutterstock.com/image-vector/croissant-pretzel-bread-icons-cupcake-cake-397645378, 2017, 2 pages.
Dexcom, “Continuous Glucose Monitoring,” Jun. 20, 2018, retrieved from https://www.dexcom.com/faq/app-g5-mobile-ios-faq, on Jul. 28, 2019, 3 pages.
Esposito A., “Implantable Glucose Sensor Featuring IDT Sensing Technology Awarded CE Mark,” Jun. 22, 2016, retrieved from https://www.medicaldesignandoutsourcing.com/implantable-glucose-sensor-featuring-idt-sensing-technology-awarded-ce-mark/, on Jul. 28, 2019, 1 page.
Examination Report for EP Application No. 14775822.1, dated Dec. 12, 2019, 4 pages.
Glum R., “Getting Started With Your Body+ Smart Scale,” Withings, Jan. 28, 2016, retrieved from https://blog.withings.com/2016/01/28/getting-started-nokia-body-plus/, on Jul. 26, 2019, 3 pages.
Hoskins M., “What's Next in Diabetes Tech for 2018?,” Jan. 11, 2018, retrieved from https://www.healthline.com/diabetesmine/diabetes-technology-expectations-2018#1, on Jul. 31, 2019,3 pages.
International Preliminary Report on Patentability for Application No. PCT/US2014/021109, dated Sep. 24, 2015, 9 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2014/021109 dated Jun. 5, 2014, 13 pages.
Iyengar V., “Connected: Diabetes Data Management Made Easy,” Aug. 2015, retrieved from https://endocrinenews.endocrine.org/august-2015-connected-diabetes-data-management-made-easy/, on Jul. 26, 2019, 2 pages.
Lovett L., “Dexcom's Integrated CGM Receives FDA Nod,” Mar. 28, 2018, retrieved from https://www.mobihealthnews.com/content/dexcoms-integrated-cgm-receives-fda-nod, on Jul. 28, 2019, 1 page.
Ryan E., et al., “What's Next from Tandem? Predictive Low Glucose Suspend Under FDA Review,” Mar. 28, 2018, retrieved from https://diatribe.org/whats-next-tandem-predictive-low-glucose-suspend-under-fda-review, on Jul. 26, 2019, 2 pages.
“Tandem Diabetes Care, Inc.—Form S-1,” Jan. 16, 2018, retrieved from http://getfilings.com/sec-filings/180116/TANDEM-DIABETES-CARE-INC_S-1/, 2 pages.
Taryn, “Tidepool: Cool New App,” Mar. 22, 2016, retrieved from https://forum.tudiabetes.org/t/tidepool-cool-new-app-for-analyzing-blood-sugartrends-thats-somuch-better-than-the-reports-i-get-with-my-pump/51854/10, on Jul. 26, 2019, 1 page.
Tran J., et al., “Smartphone-Based Glucose Monitors and Applications in the Management of Diabetes: An Overview of 10 Salient “Apps” and a Novel Smartphone-Connected Blood Glucose Monitor,” Clinical Diabetes, retrieved from https://clinical.diabetesjournals.org/content/30/4/173, on Jan. 14, 2020, vol. 30 (4), Oct. 2012, pp. 173-178.
Wills E., “Graphic Designer's Tube Maps Reveal Exactly How Far Underground You are on Every Station Platform,” Jun. 22, 2018, retrieved from https://www.standard.co.uk/news/transport/graphic-designers-tube-maps-reveal-exactly-how-far-underground-you-are-on-every-station-platform-a3870156.html, on Jul. 28, 2019, 5 pages.
Test Drive—Dexcom's G4 Platinum CGM, diatribe.org [online], published on Oct. 31, 2012, [retrieved on Feb. 5, 2021], retrieved from the Internet <URL: https://diatribe.org/issues/48/test-drive> (Year: 2012), 3 pages.
Diabetes Blog, by Sparling, sixuntilme.com [online], published on Jul. 29, 2008, [retrieved on Feb. 5, 2021], retrieved from the Internet <URL: https://sixuntilme.com/cgms/> (Year: 2008), 3 pages.
Examination Report for EP Application No. 14775822.1, dated Jan. 4, 2019, 4 pages.
Extended European Search Report for Application No. 14775822.1, dated Nov. 21, 2016, 9 pages.
Lehmann et al., “Combining rule-based reasoning and mathematical modeling in diabetes care,” Artificial Intelligence in Medicine, vol. 6, 1994, pp. 137-160.
“Natural Icons Set,” Jun. 21, 2017, retrieved from https://www.shutterstock.com/image-vector/natural-icons-set-16-filled-such-621208148, 2017, 3 pages.
Hildebrandt, “Subcutaneous Absorption of Insulin in Insulin—Dependent Diavetic patients. Influence of Species Physico-Chemical properties of Insulin and Physiological factors,” Danish Medical Bulletin, Aug. 1991, 10 pages.
Office Action dated Apr. 4, 2018 for European Application No. 14775822.1, 4 pages.
Plougmann et al., “DiasNet—a diabetes advisory system for communication and education via the internet,” International Journal of Medical Informatics, vol. 64, 2011, pp. 319-330.
Puckett et al., “A model for multiple subcutaneous insulin injections developed from individual diabetic patient data,” vol. 269, 1995, p. E1115-E1124.
Smith Medical MD Inc., “Deltec Cozmo, Personalized Insulin Pump, Starting Guide,” http://web.archive.org/web/20041207133223/http://www.cozmore.com/Library/-upload/starting.sub.˜˜guide.sub.˜˜032004.pdf, XP002497833, Dec. 7, 2004, pp. 1-83.
Stapel, “Converting Between Decimals, Fractions, and Percents,” Purplemath, 2006, 9 pages, Available at http://www.purplemath.com/modules/percents2.htm, 2006.
Trajanoski et al., Pharmacokinetic Model for the Absorption of Subcutaneously Injected Soluble Insulin and Monomeric Insulin Analogues, Biomedizinische Technik, vol. 38, No. 9. Sep. 1, 1993, pp. 224-231.
Wach et al., “Numerical Approximation of Mathematical Model for Absorption of Subcutaneously Injected Insulin,” Med & Biol. Eng & Comput., vol. 33, 1995, pp. 18-23.
Walsh et al., “Diabetes Technology-Concept 1: Super Bolus,” available at Diabetes Technology Concept 1: Super Bolus available at http://diabetesnet.com/diabetes.sub.˜˜technology/super.sub.˜˜bolus.ph-p&gt, Sep. 17, 2007, 3 pages.
Walsh et al., “Select & Test Your Correction Factor,” Pumping Insulin, Fourth Edition, Chapter 13, 2006, 10 pages.
Walsh et al., “Pumping Insulin. Everything you need for Success on a Smart insulin Pump,” Torrey Pines Press, San Diego, ISBN 1-884804-86-1, 2006, 3 pages.
Wikipedia.Com, “Wikipedia's definition for “basal rate”, ” printed from Wikipedia.com on Jun. 12, 2009, 1 page.
Wilinska et al., “Insulin Kinetics in Type-1 Diabetes: Continuous and Bolus Delivery of Rapid Acting Insulin,” IEEE Transactions on Biomedical Engineering, vol. 52, No. 1, Jan. 2005, pp. 3-12.
Related Publications (1)
Number Date Country
20200101226 A1 Apr 2020 US
Continuations (2)
Number Date Country
Parent 15072408 Mar 2016 US
Child 16590836 US
Parent 13800453 Mar 2013 US
Child 15072408 US